Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
Studying Complications after hematopoietic stem cell transplantation
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Fonds de Dotation HTC Project
- Principal Investigator
- Régis Peffault de Latour, PU-PHAssistance Publique - Hôpitaux de Paris
- Intervention
- NewSpringForMe digital solution(device)
- Enrollment
- 170 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (1)
- Service Hématologie Greffe Trèfle 3, Hôpital Saint-Louis, AP-HP, Paris, France
Collaborators
Saint-Louis Hospital, Paris, France · Nutricia Nutrition Clinique · Clinicprosport · ELLYE · Association Aïda · Gilead Sciences · Pfizer · Groupe Apicil · Association Laurette Fugain · Fondation du LEEM · Fondation AFNIC · Pierre Fabre Medicament · Novartis Pharmaceuticals · University Hospital, Clermont-Ferrand · LAPSCO, Université Clermont-Auvergne
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06148610 on ClinicalTrials.govOther trials for Complications after hematopoietic stem cell transplantation
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06625372Comparison of Intralipid With SMOF Lipid Following HSCTShahid Beheshti University
- RECRUITINGNANCT06241274Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCTUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT06198517Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCTYi Zhang
See all trials for Complications after hematopoietic stem cell transplantation →